Highlights from the American Society of Hematology (ASH) annual meeting, San Diego CA, December 3-6, 2016 – A new Canadian study has examined how often people with CML are tested to determine their response to medication (Hillis and colleagues. ASH 2016; abstract 3079). Informat
During treatment for chronic myelogenous leukemia (CML), frequent tests are needed to determine how well people are responding to their medication. Key response “milestones” have identified that an earlier, more profound response translates to a better outcome over the longer term.
Part 1 Part 2 Stem cell transplantation was initially conceived as a way of eliminating leukemia from the bone marrow much as surgery is used to remove solid tumours. However, the marrow needed to be replaced because it was the source of new blood cells, including immune cells, and a
Part 1 Throughout the 1990s, stem-cell transplantation provided a possible cure for CML, but its use declined as tyrosine kinase inhibitors (TKIs) became available starting in 2001. Medications were highly effective in controlling CML, could be taken by most people, and were generally
Part 1 A CML therapy that emerged in the 1980s was stem-cell transplantation (SCT) (Thomas and colleagues. Ann Intern Med 1986;104:155-163). The idea was that leukemia originated in the bone marrow, so destroying the bone marrow and replacing it with new cells might cure the disease t
While these standards were being developed, new laboratory techniques were enabling even more sensitive PCR testing for BCR-ABL transcripts. This opened up a new world beyond MMR – to a 4-log reduction, a 4.5-log reduction, and even a 5-log reduction.